Pfizer (PFE) Shares Sold by Mraz Amerine & Associates Inc.

Mraz Amerine & Associates Inc. lessened its stake in Pfizer (NYSE:PFE) by 17.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,506 shares of the biopharmaceutical company’s stock after selling 2,165 shares during the period. Mraz Amerine & Associates Inc.’s holdings in Pfizer were worth $381,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of PFE. Columbia Asset Management boosted its holdings in Pfizer by 1.6% in the fourth quarter. Columbia Asset Management now owns 101,946 shares of the biopharmaceutical company’s stock worth $3,692,000 after purchasing an additional 1,560 shares during the period. Bank of The Ozarks boosted its holdings in Pfizer by 24.6% in the fourth quarter. Bank of The Ozarks now owns 69,624 shares of the biopharmaceutical company’s stock worth $2,522,000 after purchasing an additional 13,728 shares during the period. Barber Financial Group Inc. acquired a new position in Pfizer in the fourth quarter worth $205,000. Rand Wealth LLC boosted its holdings in Pfizer by 0.8% in the fourth quarter. Rand Wealth LLC now owns 244,042 shares of the biopharmaceutical company’s stock worth $8,839,000 after purchasing an additional 1,892 shares during the period. Finally, Alps Advisors Inc. boosted its holdings in Pfizer by 2.0% in the fourth quarter. Alps Advisors Inc. now owns 1,386,299 shares of the biopharmaceutical company’s stock worth $50,212,000 after purchasing an additional 27,369 shares during the period. Institutional investors and hedge funds own 71.19% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of equities analysts have commented on PFE shares. Sanford C. Bernstein set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a report on Wednesday, January 17th. Morgan Stanley set a $41.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Friday, January 5th. JPMorgan Chase reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, January 30th. Finally, Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a report on Monday, January 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average price target of $39.20.

In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Charles H. Hill sold 42,393 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 248,037 shares of company stock valued at $9,064,785. Corporate insiders own 0.06% of the company’s stock.

Shares of PFE opened at $36.63 on Friday. Pfizer has a 1 year low of $31.67 and a 1 year high of $39.43. The firm has a market cap of $217,220.05, a PE ratio of 13.82, a PEG ratio of 1.83 and a beta of 0.90. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter in the previous year, the company posted $0.47 earnings per share. The company’s revenue for the quarter was up .6% compared to the same quarter last year. analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was first published by Week Herald and is owned by of Week Herald. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://weekherald.com/2018/04/21/pfizer-pfe-shares-sold-by-mraz-amerine-associates-inc.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply